Unrecognized prolonged viral replication in the pathogenesis of human RSV infection

J Clin Virol. 2018 Sep:106:1-6. doi: 10.1016/j.jcv.2018.06.014. Epub 2018 Jun 27.

Abstract

Background: Respiratory symptoms in RSV persist long after the virus is no longer detected by culture. Current concepts of RSV pathogenesis explain this by RSV inducing a long-lasting pathogenic immune cascade. We alternatively hypothesized that prolonged unrecognized RSV replication may be responsible and studied this possibility directly in a human wild-type RSV experimental infection model.

Objective: The objective of the current report was to define the duration of true human RSV replication by studying it directly in immunocompetent adults experimentally infected with a clinical strain of RSV utilizing this previously established safe and reproducible model.

Study design: 35 healthy adult volunteers were inoculated with RSV-A (Memphis-37, a low11 passage clinical strain virus, manufactured from a hospitalized bronchiolitic infant) and evaluated over 12 days. Viral load by culture, parallel quantitative PCR (genomic, message) and RSV-specific IgA, were measured twice daily from serially collected nasal washes.

Results: After inoculation, 77% (27/35) of volunteers became RSV infected. As expected, culture-detectable RSV ceased abruptly by the 5-6 t h 15 infection day. However, infected volunteers demonstrated prolonged RSV presence by both genomic and message PCR. RSV-specific IgA rose within respiratory secretions of infected volunteers during same time frame.

Conclusions: RSV replication appears to continue in humans far longer than previously thought. The rise in nasal RSV-specific IgA shortly after infection likely neutralizes culture detectable virus producing misleadingly short durations of infection. Prolonged viral replication helps explain RSV's extended disease manifestations and increases the potential utility of antivirals.

Keywords: Antiviral; IgA; Mucosal immunity; RSV; Viral load; Viral replication.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Viral / analysis
  • Antiviral Agents
  • Female
  • Healthy Volunteers
  • Humans
  • Immunocompetence
  • Immunoglobulin A / analysis*
  • Immunoglobulin A / immunology
  • Male
  • Middle Aged
  • Nose / virology
  • Polymerase Chain Reaction
  • Respiratory Syncytial Virus Infections / drug therapy
  • Respiratory Syncytial Virus Infections / immunology*
  • Respiratory Syncytial Virus, Human / pathogenicity*
  • Respiratory Syncytial Virus, Human / physiology
  • Viral Load
  • Virus Replication*
  • Young Adult

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Immunoglobulin A